Conference Service Mandl

abstract: The Business Development landscape for clinical trial service providers is changing. The rising cost of drug development, coupled with today's staggering economy has paralyzed biopharmaceutical R&D. In an effort to reduce operational expenses, biopharma companies are experimenting with different strategies that have a direct impact on your sales prospects. Clinical programs are being reprioritized, reduced or removed altogether until funding sources can be obtained. Big and small pharma are transforming their functional operations through multifaceted preferred outsourcing tactics, oftentimes reducing their flexibility to diversify external vendor pools. The process of finding leads, turning them into prospects and then closing the deal has become more challenging than ever. How you conducted business development as recently as 2-3 years ago may no longer bring you success.

abstract: ExL's 2006 Trial Design Innovation Conference was the first conference facilitating discussion on the benefits of deviating from standard drug development and outlining strategies for integrating adaptive designs into your current projects to decrease risk and increase the probability of success. Responding to increased interest in adaptive trials, over the next few years multiple events on the topic emerged with ExL distinguishing itself as the leader by consistently delivering relevant research-driven topics and the highest caliber of speakers.

abstract: Continuing a history of strong participation, the 5th Annual Pharmaceutical Pricing & Reimbursement conference will once again provide a look into how pharmaceutical companies are adjusting their pricing strategies based on the current economic climate and the rapidly changing government landscape.

abstract: The 58th Natural Products Gordon Research Conference will continue a tradition of excellence in a broad range of areas relating to natural products chemistry and isolation, novel synthetic methods, chemical biology, bioorganic and medicinal chemistry. While remaining true to its foundation of organic synthesis of natural products, the speakers in this years' outstanding lineup will deliver lectures in topics as diverse as catalytic synthetic methodology, the use of natural product like molecules as tools to probe and better understand biological systems, and recent advances in drug discovery.

abstract: Hosted by industry leader, Pfizer, this year, an exciting context is provided for pharmaceutical executives to join together in sharing best practices and concrete strategies for successful public relations and communications activities in a time of ever-present change.

abstract: Drug Discovery and Development Week in Boston, MA consists of five targeted, scientific conferences featuring practical strategies and forward-looking approaches to help attendees accelerate small molecules, antibody therapeutics and oligonucleotide therapeutics from early discovery to the clinic. Please visit www.drugdisc.com for more information.

• The Next Wave of Antibody Therapeutics – August 3-5
• Oligonucleotide Therapeutics: from Concept to Implementation – August 3-5
• Targets in Context – Linking Targets to Diseases – August 4-6
• Drug Safety Strategies to De-Risk Compounds – August 4-6
• New Frontiers in Cancer Drug Development – August 4-6

abstract: Welcome to the Target Discovery World Congress, combining our successful Screening and Ion Channel Targets conferences. This year's event will take place at the South San Francisco Conference Center. Keynote Speaker Jeffery Conn Lee E. Limbird Professor of Pharmacology Director, Vanderbilt Program in Drug Discovery Agenda Topics Target Identification and Validation Ion Channel Targets G-Protein Coupled Receptors Protein Kinase Targets Ubiquitin Targets Nuclear Receptor Targets Cell-Based Assays High Content Analysis

abstract: Welcome to the Lab-on-a-Chip World Congress, designed to review existing and new life science applications of microfluidic technologies. This year's event will take place at the South San Francisco Conference Center. The conference will be co-located with the Microarray World Congress and Molecular Diagnostics World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip. Keynote Speaker Holger Becker, Director, Microfluidic ChipShop Agenda Topics Point-of-care diagnostics Microfabrication/engineering Life science applications

abstract: The conference will be co-located with the Lab-on-a-Chip World Congress and Molecular Diagnostics World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip.

abstract: The conference will be co-located with the Microarray World Congress and Lab-on-a-Chip World Congress. Registered delegates will also have access to these meetings ensuring a very cost-effective trip.

abstract: The Pharma CI Conference & Exhibition is the premier gathering for senior level pharma, medical device, and healthcare executives in competitive intelligence. Our conference brings together the most influential experts in the field to discuss the most pressing issues in the industry. All the "Who's Who" of this sector attend annually.

abstract: Who should Attend: Investigator Initiated/Sponsored Trials, Investigator Research, Medical Affairs/Field Medical Affairs, MSL Managers/Field MSLs, Clinical Research Associates, Legal & Regulatory Affairs, Clinical and Research Investigators, Site Management, Post-Marketing Studies, Phase IV, Clinical Affairs, Clinical Data Analysts

abstract: The agenda offers tracks that are tailored to meet the needs of both new and experienced MSLs, and prepares teams for the changing dynamics of industry-KOL interactions. This highly interactive and informative event is one that cannot be missed!

abstract: This webinar is of interest to those in the pharmaceutical, biotech and medical device industries with responsibilities in the following areas:Systems Validation, Information Technology, Quality Assurance, Data Management, Regulatory Affairs, Scientific Affairs, and Software Quality Engineering

abstract: The meeting covers new scientific and business developments in antibody alternative industry and provides networking opportunities for professionals within the field. Sessions focus on recent advancements and scientific benefits, as well as business perspectives driving much of the M & A activity.

abstract: The premier global event improving biospecimen storage, distribution, and tracking to protect, prove, and validate sample integrity throughout the entire drug development process - A strategic perspective on biorepository sample management.

abstract: Prominent findings from this assessment highlight that the current environment necessitates several important things:Sharing of best practices, On going advocacy for all stakeholders, Opportunities for interactions and discussions. This conference will address these topics and issues, and will provide an environment conducive to discussing the hot topics at hand. Please join us!

abstract: Arrowhead's 3rd Annual Pain Therapeutics Summit, scheduled to take place in Summit, NJ on September 24th and September 25th, 2009, will be bringing together leaders in pain therapeutics and management to discuss the latest developments in discovery research, preclinical development, clinical development, regulatory issues and real-world pain management in the clinic.

abstract: The agenda focuses unwaveringly on methods to reduce time to market and cost of goods, to dramatically accelerate development of robust processes, to achieve higher than ever yields from cell culture, and to break through the downstream bottleneck. Choose from over 110 presentations from industry leaders as well as emerging, small- to medium-sized companies. Customize your own BPI experience to meet your needs as well as gain a comprehensive look at today's industry.

abstract: The 5th Modern Drug Discovery & Development Summit held by GTCbio (a subsidiary of Global Technology Community, LLC.) will be held on October 14-16, 2009 in San Diego, CA. The Summit provides its participants with a current look at biologics and projects into its future with discussions regarding developments and challenges in immunogenicity, humanization, drug delivery techniques for biologics, modern vaccine development, antibodies, and novel protein and peptide delivery. Overcoming the issue of the role of biologics in drug discovery and how to improve upon the length of time a drug remains effective in the body, without losing money, will be addressed.

abstract: This is the premier event for Sampling Professionals in the industry at a most crucial time in this field. Sampling Strategies are changing rapidly and to remain a leader in this environment one must stay on top of the very latest innovations and tactics.

abstract: This symposium, hosted by EORTC, NCI and AACR, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. Understanding the pathways and mechanisms which cause cancer and regulate the biological behavior of tumor cells has lead to the development of numerous new agents and innovative targets for clinical trials. This conference has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development. It will bring together delegates from all over the world igniting a huge exchange of information and promoting and developing global partnerships in translational research. Please mark your calendars for this exciting program and bookmark this page for additional information.

abstract: Welcome to the inaugural Probe Discovery conference and exhibition. This year's event will take place in beautiful La Jolla, a major biotech center and jewel of the west coast. The word 'probe' is a broad term which can be interpreted to mean any one of a wide variety of agents. These include active chemistries discovered in academic screening labs or in government (MLPCN or the NIH), commercially available probes (i.e. dyes, antibodies, fluorescent proteins), failed drug candidates from Pharma, whole body or cellular imaging agents, specific biomarkers or tool molecules from chemogenomics and/or systems biology efforts. The goal of this conference is to bring all of the various incarnations of probe hunters together to share experience and network to a common purpose. Agenda Topics: Failed Drug Candidates as Probes Dyes, Antibodies and Fluorescent Proteins Whole Body or Cellular Imaging Agents Tool Molecules from Chemogenomics Innovative Assay Technologies for Probe Discovery Confirmed Speakers: Doug Auld, Group Leader, Genomic Assay Technologies, NIH Chemical Genomics Center Thomas Chung, Project Manager, Conrad Prebys Center for Chemical Genomics, Burnham Institute for Medical Research Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Centre Sitta Sittampalam, Deputy Director - Therapeutics, Discovery and Development, University of Kansas